{"id":"ak1820","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a Phase 3 asset from Asahi Kasei Pharma, AK1820 is under clinical development for an undisclosed indication. Without public disclosure of its molecular target or mechanism of action, the exact pathway it modulates cannot be confirmed from available sources.","oneSentence":"AK1820 is an investigational therapeutic targeting immune or inflammatory pathways, though its precise mechanism remains proprietary.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:00:27.444Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT03471988","phase":"PHASE3","title":"Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis","status":"COMPLETED","sponsor":"Asahi Kasei Pharma Corporation","startDate":"2018-04-16","conditions":"Deep Mycosis","enrollment":103}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AK1820","genericName":"AK1820","companyName":"Asahi Kasei Pharma Corporation","companyId":"asahi-kasei-pharma-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}